Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi Biologics Signs Manufacturing Partnership MOU with Prima Biomed

publication date: Nov 25, 2016
WuXi Biologics, a division of CRO/CMO WuXi AppTec, signed a non-binding MOU to create a manufacturing partnership with Australia's Prima Biomed. The partnership, if finalized, would develop Prima's recombinant soluble LAG-3 protein and other LAG-3 related products as oncology drugs.  WuXi Biologics is already supplying IMP321 to Prima for clinical trials, and the new agreement would make WuXi worldwide supplier of the drug, with the exception of greater China. Eddingpharm has exclusive rights to IMP321 for greater China. More details....

Stock Symbol: (ASX: PRR; NSDQ: PRMD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here